Cincinnati Children's Research Paves Way for Newly Approved Asthma Drug
November 17, 2017
November 17, 2017
CINCINNATI, Nov. 17 -- The Cincinnati Children's Hospital Medical Center issued the following news release:
Thanks in part to nearly two decades of research at Cincinnati Children's Hospital Medical Center, the FDA has approved benralizumab, the first drug designed to specifically deplete eosinophils as a treatment for asthma.
The FDA approved benralizumab as an add-on maintenance treatment for severe asthma with eosinophil involvement. Eosinophils are a type of disease . . .
Thanks in part to nearly two decades of research at Cincinnati Children's Hospital Medical Center, the FDA has approved benralizumab, the first drug designed to specifically deplete eosinophils as a treatment for asthma.
The FDA approved benralizumab as an add-on maintenance treatment for severe asthma with eosinophil involvement. Eosinophils are a type of disease . . .